Periostin (cut-off ≥50 ng/ml) was investigated as a predictive biomarker for therapeutic effect (measured as reductions in the exacerbation rate) in Phase III trials of the anti–IL-13 mAb lebrikizumab for the treatment of uncontrolled asthma, but proved inconsistent [15]. This evidence concerns the gene IL13 and asthma.